Proglycosomes: A novel nano-vesicle for ocular delivery of tacrolimus

Garg, Vaidehi; Suri, Reshal; Jain, Gaurav K.; Kohli, Kanchan

doi:10.1016/j.colsurfb.2017.05.049

Cited by 31 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 83 Tacrolimus is a common immune modulator that has been loaded onto PLGA nanoparticle and proglycosomes to provide continuous sustained drug release without side effects ( Figure 3 ). 84 , 85 …”

Section: Conjunctivitismentioning

confidence: 99%

“… The PLGA-NPs significantly enhanced ocular bioavailability of TAC than that of aqueous suspension. V. Garg, et al 85 2017 Tacrolimus Proglycosomes Film hydration method Incorporation of proglycosomes enhanced the drug encapsulation, decreased the vesicle aggregation and increased the liposomal elasticity, thereby enhancing the transocular permeation. The developed proglycosomes are prospective carriers for enhanced ocular delivery of tacrolimus.…”

Section: Conjunctivitismentioning

confidence: 99%

“…Reprinted from Colloids Surf B Biointerfaces , 157, Garg V, Suri R, Jain GK, Kohli K. Proglycosomes: a novel nano-vesicle for ocular delivery of tacrolimus, 40–47, Copyright 2017, with permission from Elsevier. 85 Abbreviation: PNVs, Proglycosomes nano-vesicles. …”

Section: Conjunctivitismentioning

confidence: 99%

See 2 more Smart Citations

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

show abstract

Section: Conjunctivitismentioning

confidence: 99%

Section: Conjunctivitismentioning

confidence: 99%

See 1 more Smart Citation

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Ocular drug-loaded nanomedicine establishes superiority over conventional eye drops with greater bioavailability, higher therapeutic efficacy, sustained and controlled release drug profile. With the help of nano-formulation as protective shield for therapeutic agents, the drug-associated ocular irritation and local toxicity at higher drug concentrations can be reduced [67]. By choosing among a series of developed nanocarriers, along with the biodegradable and biocompatible biopolymers with mucoadhesive properties, as well as suitable excipients, constituents can be combined in different ratios to optimize the therapeutic efficacy of the tailored nanomedicine to meet specific clinical needs [30,68].…”

Section: Advantages Disadvantages and Challenges Of Nanotechnology Based Drug Delivery Systemsmentioning

confidence: 99%

“…A single subconjunctival injection of liposomal tacrolimus effectively suppressed the chemosis and congestion of conjunctival vessels, and significantly reduced the expression of IL-4 and CD4 T cells in the conjunctiva in a mice allergic conjunctivitis model (Figure 4; data not published). Modification of liposomes with edge activators such as propylene glycol (PG) or other surfactants could decrease the vesicle aggregation and increase the liposomal elasticity and therefore enhance the trans-ocular permeation [67]. This is especially useful when loading hydrophobic, high molecular weight molecules such as tacrolimus.…”

Section: Immunomodulatory Agentsmentioning

confidence: 99%

Nanotechnology for the Treatment of Allergic Conjunctival Diseases

Liu

Lin

et al. 2020

Pharmaceuticals

View full text Add to dashboard Cite

Allergic conjunctivitis is one of the most common external eye diseases and the prevalence has been increasing. The mainstay of treatment is topical eye drops. However, low bioavailability, low ocular drug penetration, transient resident time on the ocular surface due to tear turnover, frequent topical applications and dependence on patient compliance, are the main drawbacks associated with topical administration. Nanotechnology-based medicine has emerged to circumvent these limitations, by encapsulating the drugs and preventing them from degradation and therefore providing sustained and controlled release. Using a nanotechnology-based approach to load the drug is particularly useful for the delivery of hydrophobic drugs such as immunomodulatory agents, which are commonly used in allergic conjunctival diseases. In this review, different nanotechnology-based drug delivery systems, including nanoemulsions, liposomes, nanomicelles, nanosuspension, polymeric and lipid nanoparticles, and their potential ophthalmic applications, as well as advantages and disadvantages, are discussed. We also summarize the results of present studies on the loading of immunomodulators or nonsteroidal anti-inflammatory drugs to nano-scaled drug delivery systems. For future potential clinical use, research should focus on the optimization of drug delivery designs that provide adequate and effective doses with safe and satisfactory pharmacokinetic and pharmaco-toxic profiles.

show abstract